TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

Talk to your healthcare provider about TAKHZYRO

Image of speech bubbles. Talk to your healthcare provider about TAKHZYRO™ (lanadelumab-flyo).

If you’re interested in TAKHZYRO, the first step is talking to your healthcare provider about whether it could be right for you.

This Discussion Guide will give you some ideas about what to ask and how to start the conversation.

Get your guide
Image of a medical clipboard. Ask your healthcare provider about getting immediate access to TAKHZYRO™ (lanadelumab-flyo).

Getting started with TAKHZYRO

Ask your healthcare provider how you may be able to get immediate access to TAKHZYRO.

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • fast heartbeat
  • faintness
  • rash
  • hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

Please see full Prescribing Information, including information for patients.